JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Roy Buchanan reiterated a Market Outperform rating on Arbutus Biopharma (NASDAQ:ABUS) and maintained a $4 price target.
April 04, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirmed a Market Outperform rating on Arbutus Biopharma with a steady price target of $4.
The reiteration of a Market Outperform rating by a reputable analyst suggests a positive outlook on ABUS's stock performance. Maintaining a $4 price target indicates a belief in the company's potential to reach or exceed this value, likely driving investor confidence and potentially boosting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100